Vertex Pharma (VRTX) Tops Q3 EPS by 5c; bumps guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $523.93 -2.1%
EPS Growth %: -0.8%
Financial Fact:
Research and development expenses: 272.37M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
EPS Growth %: -0.8%
Financial Fact:
Research and development expenses: 272.37M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q3 EPS of $3.97, $0.05 better than the analyst estimate of $3.92. Revenue for the quarter came in at $2.48 billion versus the consensus estimate of $2.5 billion.
GUIDANCE:
Vertex Pharma sees FY2023 revenue of $9.85 billion, versus prior guidance of $9.7-$9.8 billion and consensus of $9.87 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidne
- Infosys Limited (INFY) Reports In-Line Q3 EPS
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
